MCID: MLG002
MIFTS: 47

Malignant Peritoneal Mesothelioma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Malignant Peritoneal Mesothelioma

MalaCards integrated aliases for Malignant Peritoneal Mesothelioma:

Name: Malignant Peritoneal Mesothelioma 56
Diffuse Malignant Peritoneal Mesothelioma 56
Primary Malignant Peritoneal Mesothelioma 56
Malignant Mesothelioma of Peritoneum 69

Characteristics:

Orphanet epidemiological data:

56
malignant peritoneal mesothelioma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (France),1-9/100000 (Europe),1-9/1000000 (Italy); Age of onset: Adult; Age of death: adult;

Classifications:



Summaries for Malignant Peritoneal Mesothelioma

MalaCards based summary : Malignant Peritoneal Mesothelioma, also known as diffuse malignant peritoneal mesothelioma, is related to ocular melanoma and peritoneal mesothelioma, and has symptoms including ascites, weight loss and abnormality of coagulation. An important gene associated with Malignant Peritoneal Mesothelioma is VIM (Vimentin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Pathways in cancer. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include t cells, colon and pancreas, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Related Diseases for Malignant Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Malignant Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 178)
id Related Disease Score Top Affiliating Genes
1 ocular melanoma 29.4 CDKN2A EGFR MUC1
2 peritoneal mesothelioma 11.6
3 peritonitis 10.9
4 2q31.1 microdeletion syndrome 10.5 MUC1 VIM
5 spleen angiosarcoma 10.5 MUC1 VIM
6 myoma 10.5 MUC1 VIM
7 laryngeal neuroendocrine tumor 10.5 MUC1 VIM
8 hip subluxation 10.5 EGFR VIM
9 mannose-binding lectin protein deficiency 10.5 MUC1 VIM
10 vulvar angiokeratoma 10.5 MUC1 VIM
11 reticular pattern testicular yolk sac tumor 10.5 MUC1 VIM
12 pyoderma 10.4 MUC1 VIM
13 amelogenesis imperfecta local hypoplastic 10.4 CDKN2A VIM
14 pancreatic intraductal papillary-colloid carcinoma 10.4 MUC1 VIM
15 cellular ependymoma 10.4 MUC1 VIM
16 lice infestation 10.4 MUC1 VIM
17 lymphangiosarcoma 10.4 MUC1 VIM
18 ganglioglioma 10.4 MUC1 VIM
19 fallopian tube germ cell cancer 10.4 MUC1 VIM
20 ovary papillary carcinoma 10.4 MUC1 VIM
21 childhood pleomorphic rhabdomyosarcoma 10.4 MUC1 VIM
22 vulvar squamous papilloma 10.4 MUC1 VIM
23 pancreatic serous cystadenoma 10.4 MUC1 VIM
24 sebaceous adenoma 10.4 MUC1 VIM
25 subependymal glioma 10.4 MUC1 VIM
26 short-rib thoracic dysplasia 12 10.4 MUC1 VIM
27 ovarian mucinous adenocarcinoma 10.4 MUC1 VIM
28 coronary restenosis 10.4 MUC1 VIM
29 extraskeletal mesenchymal chondrosarcoma 10.4 MUC1 VIM
30 spondyloepimetaphyseal dysplasia, isidor type 10.4 MUC1 VIM
31 subglottis verrucous carcinoma 10.4 EGFR MUC1
32 pancreatic ductal carcinoma 10.4 MUC1 VIM
33 secondary syphilis 10.4 MUC1 VIM
34 pulmonary venoocclusive disease 10.4 MUC1 VIM
35 mesenchymoma 10.4 MUC1 VIM
36 malignant giant cell tumor of soft parts 10.4 CDKN2A EGFR
37 prostate disease 10.4 MUC1 VIM
38 luminal breast carcinoma 10.4 EGFR MUC1
39 dense deposit disease 10.4 MUC1 VIM
40 vulvar keratoacanthoma-like carcinoma 10.4 MUC1 VIM
41 patent ductus arteriosus and bicuspid aortic valve with hand anomalies 10.4 MUC1 VIM
42 spindle epithelial tumor with thymus-like differentiation tumor 10.4 CDKN2A EGFR
43 polyosteolysis/hyperostosis syndrome 10.4 MUC1 VIM
44 rete testis neoplasm 10.4 CDKN2A EGFR
45 kidney benign neoplasm 10.4 MUC1 VIM
46 mitochondrial myopathy with lactic acidosis 10.4 MUC1 VIM
47 multiple carboxylase deficiency 10.4 CDKN2A EGFR
48 mediastinal osteogenic sarcoma 10.4 MUC1 VIM
49 acute allergic serous otitis media 10.3 MUC1 VIM
50 middle ear squamous cell carcinoma 10.3 CDKN2A EGFR

Graphical network of the top 20 diseases related to Malignant Peritoneal Mesothelioma:



Diseases related to Malignant Peritoneal Mesothelioma

Symptoms & Phenotypes for Malignant Peritoneal Mesothelioma

Human phenotypes related to Malignant Peritoneal Mesothelioma:

56 32 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 56 32 hallmark (90%) Very frequent (99-80%) HP:0001541
2 weight loss 56 32 frequent (33%) Frequent (79-30%) HP:0001824
3 abnormality of coagulation 56 32 occasional (7.5%) Occasional (29-5%) HP:0001928
4 abdominal pain 56 32 hallmark (90%) Very frequent (99-80%) HP:0002027
5 dyspnea 56 32 occasional (7.5%) Occasional (29-5%) HP:0002094
6 peritonitis 56 32 hallmark (90%) Very frequent (99-80%) HP:0002586
7 ileus 56 32 occasional (7.5%) Occasional (29-5%) HP:0002595
8 neoplasm 56 32 hallmark (90%) Very frequent (99-80%) HP:0002664
9 abdominal distention 56 32 hallmark (90%) Very frequent (99-80%) HP:0003270
10 edema of the lower limbs 56 32 occasional (7.5%) Occasional (29-5%) HP:0010741

UMLS symptoms related to Malignant Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 EGFR MUC1 NF2 VIM
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 8.8 EGFR MUC1 VIM

MGI Mouse Phenotypes related to Malignant Peritoneal Mesothelioma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.35 BIRC5 CDKN2A EGFR NF2 VIM
2 respiratory system MP:0005388 8.92 CDKN2A EGFR NF2 VIM

Drugs & Therapeutics for Malignant Peritoneal Mesothelioma

Drugs for Malignant Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Doxil Approved June 1999 Phase 3,Phase 2 31703
3 Ranpirnase Investigational Phase 3 196488-72-9
4 Anti-Bacterial Agents Phase 3,Phase 2
5 Antibiotics, Antitubercular Phase 3,Phase 2
6 Topoisomerase Inhibitors Phase 3,Phase 2
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
9
Gemcitabine Approved Phase 2 95058-81-4 60750
10
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
11
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
12
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
13
Fluorouracil Approved Phase 2 51-21-8 3385
14
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
15
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
16
Pancrelipase Approved Phase 2 53608-75-6
17
Promethazine Approved Phase 2 60-87-7 4927
18
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
19
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
20
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
21
Pembrolizumab Approved Phase 2 1374853-91-4
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3
23
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
24
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
25
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
28
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
29 Anti-Infective Agents Phase 2,Phase 1
30 Antimetabolites Phase 2
31 Antimetabolites, Antineoplastic Phase 2
32 Antiviral Agents Phase 2,Phase 1
33 Immunosuppressive Agents Phase 2,Phase 1
34 Alkylating Agents Phase 2,Phase 1
35 Interferon-gamma Phase 2
36 interferons Phase 2,Phase 1
37 Mitomycins Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
39
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
40 Protein Kinase Inhibitors Phase 2,Phase 1
41 Folic Acid Antagonists Phase 2,Phase 1
42 Vitamin B Complex Phase 2,Phase 1
43 Albumin-Bound Paclitaxel Phase 2,Phase 1
44 Antimitotic Agents Phase 2,Phase 1
45 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
46 Cortisol succinate Phase 2
47 Hydrocortisone 17-butyrate 21-propionate Phase 2
48 Hydrocortisone acetate Phase 2
49 pancreatin Phase 2
50 Pharmaceutical Solutions Phase 2

Interventional clinical trials:

(show all 31)

id Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
4 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
5 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2 erlotinib hydrochloride
6 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
7 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
8 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Recruiting NCT02588131 Phase 2 tremelimumab plus MEDI4736
9 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Recruiting NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
10 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT02588781 Phase 2 Pemetrexed
11 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
12 Pembrolizumab in Treating Patients With Malignant Mesothelioma Recruiting NCT02399371 Phase 2
13 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
14 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
15 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Active, not recruiting NCT01160458 Phase 2 IMC-A12
16 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Active, not recruiting NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
17 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2
18 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1 Tremelimumab;MEDI4736
19 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
20 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02029690 Phase 1 ADI-PEG 20
21 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
22 CAR T Cells in Mesothelin Expressing Cancers Recruiting NCT03054298 Phase 1
23 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1 BAY94-9343;BAY94-9343 (Expansion);BAY94-9343 (1.8 mg/kg);BAY94-9343 (2.2 mg/kg)
24 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
25 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
26 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Sur Recruiting NCT01416714
27 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
28 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
29 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
30 International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Recruiting NCT03210298
31 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Malignant Peritoneal Mesothelioma

Genetic Tests for Malignant Peritoneal Mesothelioma

Anatomical Context for Malignant Peritoneal Mesothelioma

MalaCards organs/tissues related to Malignant Peritoneal Mesothelioma:

39
T Cells, Colon, Pancreas, Lung, Lymph Node, Testis, Liver

Publications for Malignant Peritoneal Mesothelioma

Articles related to Malignant Peritoneal Mesothelioma:

(show top 50) (show all 273)
id Title Authors Year
1
Presentation of a malignant peritoneal mesothelioma in the forma of rough hepatic calcifications. ( 28480727 )
2017
2
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. ( 28189456 )
2017
3
Unusual presentation of a late-onset recurrence of malignant peritoneal mesothelioma. ( 28264807 )
2017
4
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. ( 28594258 )
2017
5
Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma. ( 28215643 )
2017
6
Malignant peritoneal mesothelioma: a review. ( 28706904 )
2017
7
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. ( 28849389 )
2017
8
A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis. ( 28646342 )
2017
9
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. ( 28123552 )
2017
10
Malignant peritoneal mesothelioma - a rare cause of laparotomy. ( 28702106 )
2017
11
Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. ( 28324285 )
2017
12
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. ( 28910456 )
2017
13
miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. ( 28716051 )
2017
14
A Rare Case of Biphasic Malignant Peritoneal Mesothelioma with Refractory Ascites. ( 28381756 )
2017
15
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation. ( 28469343 )
2017
16
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. ( 28877056 )
2017
17
Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma. ( 27428868 )
2016
18
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis. ( 26645426 )
2016
19
Malignant peritoneal mesothelioma and Crohn disease. ( 27484913 )
2016
20
A Case of Encapsulating Peritoneal Sclerosis Complicated by Malignant Peritoneal Mesothelioma. ( 27628605 )
2016
21
The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. ( 27858567 )
2016
22
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. ( 27472649 )
2016
23
Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization-array. ( 27184482 )
2016
24
Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma. ( 27612411 )
2016
25
Renal cell carcinoma and malignant peritoneal mesothelioma after occupational asbestos exposure: case report. ( 27240221 )
2016
26
Diffuse malignant peritoneal mesothelioma presenting with psammomatous calcification on a cervical smear: A case report. ( 27773157 )
2016
27
Diagnosis and management of patients with malignant peritoneal mesothelioma. ( 26941986 )
2016
28
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. ( 26810896 )
2016
29
Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy. ( 27858561 )
2016
30
A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma. ( 27187383 )
2016
31
Preventing recurrence of diffuse malignant peritoneal mesothelioma. ( 27486718 )
2016
32
Malignant peritoneal mesothelioma in a patient with intestinal fistula, incisional hernia and abdominal infection: A case report. ( 26998119 )
2016
33
Computed Tomographic Features of Malignant Peritoneal Mesothelioma. ( 26976999 )
2016
34
CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis. ( 26661955 )
2016
35
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. ( 27813512 )
2016
36
A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype. ( 27438989 )
2016
37
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report. ( 27902597 )
2016
38
Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases. ( 27281118 )
2016
39
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma. ( 27858557 )
2016
40
Malignant peritoneal mesothelioma diagnosed by EUS-guided tissue acquisition. ( 26643708 )
2015
41
The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). ( 26572754 )
2015
42
Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment. ( 26545374 )
2015
43
Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase III+, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray. ( 25777091 )
2015
44
Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. ( 25798586 )
2015
45
Malignant peritoneal mesothelioma without asbestos exposure: An ovarian cancer imitator. ( 26076085 )
2015
46
Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. ( 25948791 )
2015
47
Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencing. ( 26070481 )
2015
48
Diffuse Malignant Peritoneal Mesothelioma Presenting with Psammomatous Calcification on a Cervical Smear. ( 26845517 )
2015
49
Unusual Appearance of Malignant Peritoneal Mesothelioma. ( 25793652 )
2015
50
The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. ( 26493618 )
2015

Variations for Malignant Peritoneal Mesothelioma

Expression for Malignant Peritoneal Mesothelioma

Search GEO for disease gene expression data for Malignant Peritoneal Mesothelioma.

Pathways for Malignant Peritoneal Mesothelioma

GO Terms for Malignant Peritoneal Mesothelioma

Biological processes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein sumoylation GO:0016925 9.16 BIRC5 CDKN2A
2 regulation of protein stability GO:0031647 8.96 CDKN2A NF2
3 negative regulation of cell-matrix adhesion GO:0001953 8.62 CDKN2A NF2

Sources for Malignant Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....